Barinka Lab, Institute of Biotechnology of the Czech Academy of Sciences

About the Barinka Lab

Cyril Bařinka, PhD spent five years at the NIH National Cancer Institute before starting his own lab at the Institute of Biotechnology of the Czech Academy of Sciences in 2010. Dr. Bařinka is known for his expertise in the biochemistry and structure-function of the histone deacetylase (HDAC) enzyme gene family. Recently, Dr. Barinka has begun exploring HDAC6 inhibition as a potential therapeutic for KAND. This project leverages Dr. Bařinka’s expertise and assay technology, which enables scientists to measure the activity and potential effectiveness of HDAC6 inhibition in a mouse model of KAND. Through our partnership, the Bařinka Lab to collaborates with HNF Pharma Inc. and The Jackson Laboratory to study a potential drug therapy for KIF1A Associated Neurological Disorder.